Background The Cryptococcus neoformans/C. gattii species complex comprises two sibling species that are divided into eight major molecular types, C. neoformans VNI to VNIV and C. gattii VGI to VGIV. These genotypes differ in host range, epidemiology, virulence, antifungal susceptibility and geographic distribution. The currently used phenotypic and molecular identification methods for the species/molecular types are time consuming and expensive. As Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry (MALDI-TOF MS) offers an effective alternative for the rapid identification of microorganisms, the objective of this study was to examine its potential for the identification of C. neoformans and C. gattii strains at the intra- and inter-species level. Methodology Protein extracts obtained via the formic acid extraction method of 164 C. neoformans/C. gattii isolates, including four inter-species hybrids, were studied. Results The obtained mass spectra correctly identified 100% of all studied isolates, grouped each isolate according to the currently recognized species, C. neoformans and C. gattii, and detected potential hybrids. In addition, all isolates were clearly separated according to their major molecular type, generating greater spectral differences among the C. neoformans molecular types than the C. gattii molecular types, most likely reflecting a closer phylogenetic relationship between the latter. The number of colonies used and the incubation length did not affect the results. No spectra were obtained from intact yeast cells. An extended validated spectral library containing spectra of all eight major molecular types was established. Conclusions MALDI-TOF MS is a rapid identification tool for the correct recognition of the two currently recognized human pathogenic Cryptococcus species and offers a simple method for the separation of the eight major molecular types and the detection of hybrid strains within this species complex in the clinical laboratory. The obtained mass spectra provide further evidence that the major molecular types warrant variety or even species status.
References
[1]
Kwon-Chung KJ, Boekhout T, Wickes BL, Fell JW (2011) Systematic of the genus Cryptococcus and its type species C. neoformans. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (2011) Cryptococcus: From Human Pathogen to Model Yeast Washington, DC. ASM Press. pp. 3–15.
[2]
Bovers M, Hagen F, Boekhout T (2008) Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Micol 25: S4–S12.
[3]
Mitchell TG, Perfect JR (1995) Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8: 515–548.
[4]
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23. pp. 525–530.
Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, et al. (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). PNAS 101: 17258–17263.
[7]
Kwon-Chung J, Polacheck I, Bennett J (1982) Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol 15: 535–537.
[8]
Meyer W, Mitchell TG (1995) Polymerase chain reaction fingerprinting in fungi using single primers specific to minisatellites and simple repetitive DNA sequences: strain variation in Cryptococcus neoformans. Electrophoresis 16: 1648–1656.
[9]
Meyer W, Marszewska K, Amirmostofian M, Igreja RP, Hardtke C, et al. (1999) Molecular typing of global isolates of Cryptococcus neoformans var neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA – a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis 20: 1790–1799.
[10]
Meyer W, Casta？eda A, Jackson S, Huynh M, Casta？eda E, et al. (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9: 189–195.
[11]
Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, et al. (2001) Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology 147: 891–907.
[12]
Hanafy A, Kaocharoen S, Jover-Botella A, Katsu M, Iida S, et al. (2008) Multilocus microsatellite typing for Cryptococcus neoformans var. grubii. Med Mycol 46: 685–696.
[13]
Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, et al. (2009) Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol 47: 561–570.
[14]
Ngamskulrungroj P, Gilgado F, Faganello J, Litvintseva AP, Leal AL, et al. (2009) Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii Deserves to Have Varieties. PLoS ONE 4: e5862.
[15]
Kwon-Chung KJ, Bennett JE (1984) Epidemiologic differences between the two varieties of Cryptococcus neoformans. Am J Epidemiol 120: 123–130.
[16]
Byrnes EJ, Li W, Lewit Y, Ma H, Voelz K, et al. (2010) Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the Northwest United States. PLoS Pathog 6: e1000850.
[17]
Chong HS, Dagg R, Malik R, Chen S, Carter D (2010) In Vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J Clin Microbiol 48: 4115–4120.
Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M (2011) Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol. doi:10.3109/13693786.2011.602126.
[20]
Costa JJ, Freire AK, Aguiar R, Nogueira RS, Araújo FE, et al. (2010) Molecular methods for the diagnosis and characterization of Cryptococcus: a review. Can J Microbiol 56: 445–458.
[21]
McTaggart L, Richardson SE, Seah C, Hoang L, Fothergill A, et al. (2011) Rapid identification of Cryptococcus neoformans var. grubii, C. neoformans var. neoformans, and C. gattii by use of rapid biochemical tests, differential media, and DNA sequencing. J Clin Microbiol 49: 2522–2527.
[22]
Hettick JM, Kashon ML, Slaven JE, Ma Y, Simpson JP, et al. (2006) Discrimination of intact mycobacteria at the strain level: A combined MALDI-TOF MS and biostatistical analysis. Proteomics 6: 6416–6425.
[23]
Neville SA, LeCordier A, Ziochos H, Chater MJ, Gosbell IB, et al. (2011) The Utility of matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) following introduction for routine laboratory bacterial identification. J Clin Microbiol. doi:10.1128/JCM.00431–11.
[24]
Cassagne C, Ranque S, Normand AC, Fourquet P, Thiebault S, et al. (2011) Mould routine identification in the clinical laboratory by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. PLoS One 6: e28425.
[25]
Coulibaly O, Marinach-Patrice C, Cassagne C, Piarroux R, Mazier D, et al. (2011) Pseudallescheria/Scedosporium complex species identification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Med Mycol 49: 621–626.
[26]
Marklein G, Josten M, Klanke U, Müller E, Horré R, et al. (2009) Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates. J Clin Microbiol 47: 2912–2917.
[27]
McTaggart L, Lei E, Richardson SE, Hoang L, Fothergill A, et al. (2011) Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 49: 3050–3053.
[28]
Pinto A, Halliday C, Zahra M, van Hal S, Olma T, et al. (2011) Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One 6: e25712.
[29]
Qian J, Cutler JE, Cole RB, Cai J (2008) MALDI-TOF mass signatures for differentiation of yeast species, strain grouping and monitoring of morphogenesis markers. Anal Bioanal Chem 392: 439–449.
[30]
Santos C, Paterson RR, Venancio A, Lima N (2010) Filamentous fungal characterizations by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Appl Microbiol 108: 375–385.
[31]
Stevenson LG, Drake SK, Shea YR, Zelazny Am, Murray PR (2010) Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species. J Clin Micorbiol 48: 3482–3486.
[32]
Bizzini A, Greub G (2010) Matrix-assisted laser desorption ionization time-of-flight mass spectrometry, a revolution in clinical microbial identification. Clin Microbiol Infect 16: 1614–1619.
[33]
Hettick JM, Green BJ, Buskirk AD, Slaven JE, Kashon ML, et al. (2011) Chapter 3, Discrimination of Fungi by MALDI-TOF Mass Spectrometry. In: Fenselau C, et al., editor. Rapid Characterization of Microorganisms by Mass Spectrometry; ACS Symposium Series; American Chemical Society: Washington, DC. pp. 35–50.
[34]
Aminnejad M, Diaz M, Arabatzis M, Casta？eda E, Lazera M, et al. (2011) Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococcus gattii VGII. Mycopathologia. doi:10.1007/s11046–011–9491-x.
[35]
Meyer W, Gilgado F, Ngamskulrungroj P, Trilles L, Hagen F, et al. (2011) Molecular typing of the Cryptococcus neoformans/Cryptococcus gattii species complex. In: J InHeitman, TR Kozel, KJ Kwon-Chung, JR Perfect, editors. Casadevall A. Cryptococcus: From Human Pathogen to Model Yeast Washington, DC. ASM. pp. 327–357.
[36]
Bovers M, Hagen F, Kuramae EE, Diaz MR, Spanjaard L, et al. (2006) Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res 6: 599–607.
[37]
Bovers M, Hagen F, Kuramae EE, Hoogveld HL, Dromer F, et al. (2008) AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis 14: 1105–1108.
[38]
Cogliati M, Barchiesi F, Spreghini E, Tortorano AM (2011) Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. Mycopathologia. doi:10.1007/s11046–011–9467-x.
[39]
Litvintseva AP, Lin X, Templeton I, Heitman J, Mitchell TG (2007) Many globally isolated AD hybrid strains of Cryptococcus neoformans originated in Africa. PLoS Pathog 3: e114.
[40]
Tsuchihashi Z, Dracopoli NC (2002) Progress in high throughput SNP genotyping methods. The Pharmacogenomics Journal 2: 103–110.
[41]
Espinel-Ingroff A, Kish CW , Kerkering TM, Fromtling RA, Bartizal K, et al. (1992) Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J Clin Microbiol 30: 3138–3145.
[42]
Diaz MR, Boekhout T, Kiesling T, Fell JW (2005) Comparative analysis of the intergenic spacer regions and population structure of the species complex of the pathogenic yeast Cryptococcus neoformans. FEMS Yeast Res 5: 1129–1140.
[43]
Kwon-Chung KJ, Edman JC, Wickes BL (1992) Genetic association of mating types and virulence in Cryptococcus neoformans. Infect Immun 60: 602–605.
[44]
Viviani MA, Esposto MC, Cogliati M, Montagna MT, Wickes BL (2001) Isolation of a Cryptococcus neoformans serotype A MATa strain from the Italian environment. Med Mycol 39: 383–386.
[45]
Franzot SP, Salkin IF, Casadevall A (1999) Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 37: 838–840.
[46]
Chen S, Sorrell T, Nimmo G, Speed B, Currie B, et al. (2000) Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 31: 499–508.
[47]
Velegraki A, Kiosses VG, Pitsouni H, Toukas D, Daniilidis VD, et al. (2001) First report of Cryptococcus neoformans var. gattii serotype B from Greece. Med Mycol 39: 419–422.
[48]
Kluger EK, Karaoglu HK, Krockenberger MB, Della Torre PK, Meyer W, et al. (2006) Recrudescent cryptococcosis, caused by Cryptococcus gattii (molecular type VGII), over a 13-year period in a Birman cat. Med Mycol 44: 561–566.
[49]
Meyer W, Vasilyeva NV, Yelinov NP, Thileva YA, Bogomolova TS (2003) DNA Analysis in the Genome in Cryptococcus neoformans isolated from patients in Russia by PCR-fingerprinting and RAPDF methods. Problems in Medical Mycology T.5 N3: 8–11.
[50]
Lemmer K, Naumann D, Raddatz B, Tintelnot K (2004) Molecular typing of Cryptococcus neoformans by PCR fingerprinting, in comparison with serotyping and Fourier transform infrared-spectroscopy-based phenotyping. Med Mycol 42: 135–147.
[51]
Chen SC, Brownlee AG, Sorrell TC, Ruma P, Nimmo G (1996) Identification by random amplification of polymorphic DNA of a common molecular type of Cryptococcus neoformans var. neoformans in patients with AIDS or other immunosuppressive conditions. J Infect Dis 173: 754–758.
